Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy
Background: The Greek substudy of the Tamoxifen and Exemestane Adjuvant Multicenter International trial compared the effect of exemestane on the lipid profile of postmenopausal, breast cancer patients to that of tamoxifen in the adjuvant setting. Patients and methods: Lipidemic profile changes were...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2009-01, Vol.20 (1), p.49-55 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | 1 |
| container_start_page | 49 |
| container_title | Annals of oncology |
| container_volume | 20 |
| creator | Markopoulos, C. Polychronis, A. Dafni, U. Koukouras, D. Zobolas, V. Tzorakoleftherakis, E. Xepapadakis, G. Gogas, H. |
| description | Background: The Greek substudy of the Tamoxifen and Exemestane Adjuvant Multicenter International trial compared the effect of exemestane on the lipid profile of postmenopausal, breast cancer patients to that of tamoxifen in the adjuvant setting.
Patients and methods: Lipidemic profile changes were studied in 142 postmenopausal patients randomized to receive either adjuvant exemestane (n = 77) or tamoxifen (n = 65). Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and serum triglyceride (TRG) levels were measured at baseline and then every 3 months for the first 12 months of treatment and at 18 and 24 months.
Results: A trend for a reduction in TC was found in both treatment arms; however, TC and LDL levels were consistently and significantly decreased in tamoxifen arm only. The mean HDL level was higher for the tamoxifen arm compared with the exemestane arm across time. No significant trend was detected throughout the study period on TRG levels on either arm.
Conclusions: Unlike tamoxifen's beneficial effect on TC and LDL levels, exemestane appears to have a neutral effect on lipidemic profile of postmenopausal, breast cancer patients. These data offer additional information with regard to the safety and tolerability of exemestane treatment in the adjuvant setting. |
| doi_str_mv | 10.1093/annonc/mdn545 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_196631980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdn545</oup_id><els_id>S0923753419399612</els_id><sourcerecordid>1631051301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-4a515e6ce23c9a5f7ea8b8a2709696a9c47b27ac16988e27779b7ae92a6e27873</originalsourceid><addsrcrecordid>eNqF0U1rFTEUBuAgir2tLt1KEAQ3Y5P5yIe7Utte8YpdVLi4CWcyZ2zaO5lpkpH235syl7oSVyHk4ZyXN4S84ewjZ7o6Bu9Hb4-Hzjd184yseCN0oVjNn5MV02VVyKaqD8hhjDeMMaFL_ZIccCWkkkKsiNu4yXXUXoP_hZE6T9uAEBO14C0GOkFy6FOko6d4jwPGBB5pyigN-eET7Z2HHQ0Y590j62m6Rnp1dvKNXgTEWxrnNqa5e3hFXvSwi_h6fx6RH-dnV6frYvP94svpyaawDROpqKHhDQqLZWU1NL1EUK2CUjIttABta9mWEiwXWikspZS6lYC6BJFvSlZH5N0ydwrj3ZzzmptxDjljNFwLUXGtWEbFgmwYYwzYmym4AcKD4cw89mqWXs3Sa_Zv90PndsDur94XmcH7PYBoYdeHXJ-LT67kJas1V9l9WNw4T__duc_oYsL7Jwzh1ghZycastz_N5eW2EtvPX806e7l4zO3-dhhMtPnvLHYuoE2mG90_Nv0BiZ2zrw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196631980</pqid></control><display><type>article</type><title>Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Markopoulos, C. ; Polychronis, A. ; Dafni, U. ; Koukouras, D. ; Zobolas, V. ; Tzorakoleftherakis, E. ; Xepapadakis, G. ; Gogas, H.</creator><creatorcontrib>Markopoulos, C. ; Polychronis, A. ; Dafni, U. ; Koukouras, D. ; Zobolas, V. ; Tzorakoleftherakis, E. ; Xepapadakis, G. ; Gogas, H.</creatorcontrib><description>Background: The Greek substudy of the Tamoxifen and Exemestane Adjuvant Multicenter International trial compared the effect of exemestane on the lipid profile of postmenopausal, breast cancer patients to that of tamoxifen in the adjuvant setting.
Patients and methods: Lipidemic profile changes were studied in 142 postmenopausal patients randomized to receive either adjuvant exemestane (n = 77) or tamoxifen (n = 65). Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and serum triglyceride (TRG) levels were measured at baseline and then every 3 months for the first 12 months of treatment and at 18 and 24 months.
Results: A trend for a reduction in TC was found in both treatment arms; however, TC and LDL levels were consistently and significantly decreased in tamoxifen arm only. The mean HDL level was higher for the tamoxifen arm compared with the exemestane arm across time. No significant trend was detected throughout the study period on TRG levels on either arm.
Conclusions: Unlike tamoxifen's beneficial effect on TC and LDL levels, exemestane appears to have a neutral effect on lipidemic profile of postmenopausal, breast cancer patients. These data offer additional information with regard to the safety and tolerability of exemestane treatment in the adjuvant setting.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdn545</identifier><identifier>PMID: 18678766</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adenocarcinoma - blood ; Adenocarcinoma - drug therapy ; Adenocarcinoma - metabolism ; Adenocarcinoma - surgery ; Androstadienes - adverse effects ; Androstadienes - therapeutic use ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; aromatase inhibitors ; Biological and medical sciences ; breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - surgery ; Chemotherapy, Adjuvant ; cholesterol ; Cross-Over Studies ; exemestane ; Female ; Greece ; Gynecology. Andrology. Obstetrics ; Humans ; Lipid Metabolism - drug effects ; lipids ; Lipids - blood ; Mammary gland diseases ; Medical sciences ; Pharmacology. Drug treatments ; Postmenopause - blood ; Postmenopause - drug effects ; Postmenopause - metabolism ; tamoxifen ; Tamoxifen - therapeutic use ; TEAM trial ; Tumors</subject><ispartof>Annals of oncology, 2009-01, Vol.20 (1), p.49-55</ispartof><rights>2008 European Society for Medical Oncology</rights><rights>The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org 2009</rights><rights>2009 INIST-CNRS</rights><rights>The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-4a515e6ce23c9a5f7ea8b8a2709696a9c47b27ac16988e27779b7ae92a6e27873</citedby><cites>FETCH-LOGICAL-c506t-4a515e6ce23c9a5f7ea8b8a2709696a9c47b27ac16988e27779b7ae92a6e27873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21204918$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18678766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Markopoulos, C.</creatorcontrib><creatorcontrib>Polychronis, A.</creatorcontrib><creatorcontrib>Dafni, U.</creatorcontrib><creatorcontrib>Koukouras, D.</creatorcontrib><creatorcontrib>Zobolas, V.</creatorcontrib><creatorcontrib>Tzorakoleftherakis, E.</creatorcontrib><creatorcontrib>Xepapadakis, G.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><title>Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: The Greek substudy of the Tamoxifen and Exemestane Adjuvant Multicenter International trial compared the effect of exemestane on the lipid profile of postmenopausal, breast cancer patients to that of tamoxifen in the adjuvant setting.
Patients and methods: Lipidemic profile changes were studied in 142 postmenopausal patients randomized to receive either adjuvant exemestane (n = 77) or tamoxifen (n = 65). Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and serum triglyceride (TRG) levels were measured at baseline and then every 3 months for the first 12 months of treatment and at 18 and 24 months.
Results: A trend for a reduction in TC was found in both treatment arms; however, TC and LDL levels were consistently and significantly decreased in tamoxifen arm only. The mean HDL level was higher for the tamoxifen arm compared with the exemestane arm across time. No significant trend was detected throughout the study period on TRG levels on either arm.
Conclusions: Unlike tamoxifen's beneficial effect on TC and LDL levels, exemestane appears to have a neutral effect on lipidemic profile of postmenopausal, breast cancer patients. These data offer additional information with regard to the safety and tolerability of exemestane treatment in the adjuvant setting.</description><subject>Adenocarcinoma - blood</subject><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - metabolism</subject><subject>Adenocarcinoma - surgery</subject><subject>Androstadienes - adverse effects</subject><subject>Androstadienes - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>aromatase inhibitors</subject><subject>Biological and medical sciences</subject><subject>breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - surgery</subject><subject>Chemotherapy, Adjuvant</subject><subject>cholesterol</subject><subject>Cross-Over Studies</subject><subject>exemestane</subject><subject>Female</subject><subject>Greece</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Lipid Metabolism - drug effects</subject><subject>lipids</subject><subject>Lipids - blood</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Postmenopause - blood</subject><subject>Postmenopause - drug effects</subject><subject>Postmenopause - metabolism</subject><subject>tamoxifen</subject><subject>Tamoxifen - therapeutic use</subject><subject>TEAM trial</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U1rFTEUBuAgir2tLt1KEAQ3Y5P5yIe7Utte8YpdVLi4CWcyZ2zaO5lpkpH235syl7oSVyHk4ZyXN4S84ewjZ7o6Bu9Hb4-Hzjd184yseCN0oVjNn5MV02VVyKaqD8hhjDeMMaFL_ZIccCWkkkKsiNu4yXXUXoP_hZE6T9uAEBO14C0GOkFy6FOko6d4jwPGBB5pyigN-eET7Z2HHQ0Y590j62m6Rnp1dvKNXgTEWxrnNqa5e3hFXvSwi_h6fx6RH-dnV6frYvP94svpyaawDROpqKHhDQqLZWU1NL1EUK2CUjIttABta9mWEiwXWikspZS6lYC6BJFvSlZH5N0ydwrj3ZzzmptxDjljNFwLUXGtWEbFgmwYYwzYmym4AcKD4cw89mqWXs3Sa_Zv90PndsDur94XmcH7PYBoYdeHXJ-LT67kJas1V9l9WNw4T__duc_oYsL7Jwzh1ghZycastz_N5eW2EtvPX806e7l4zO3-dhhMtPnvLHYuoE2mG90_Nv0BiZ2zrw</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Markopoulos, C.</creator><creator>Polychronis, A.</creator><creator>Dafni, U.</creator><creator>Koukouras, D.</creator><creator>Zobolas, V.</creator><creator>Tzorakoleftherakis, E.</creator><creator>Xepapadakis, G.</creator><creator>Gogas, H.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>6I.</scope><scope>AAFTH</scope><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20090101</creationdate><title>Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy</title><author>Markopoulos, C. ; Polychronis, A. ; Dafni, U. ; Koukouras, D. ; Zobolas, V. ; Tzorakoleftherakis, E. ; Xepapadakis, G. ; Gogas, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-4a515e6ce23c9a5f7ea8b8a2709696a9c47b27ac16988e27779b7ae92a6e27873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adenocarcinoma - blood</topic><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - metabolism</topic><topic>Adenocarcinoma - surgery</topic><topic>Androstadienes - adverse effects</topic><topic>Androstadienes - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>aromatase inhibitors</topic><topic>Biological and medical sciences</topic><topic>breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - surgery</topic><topic>Chemotherapy, Adjuvant</topic><topic>cholesterol</topic><topic>Cross-Over Studies</topic><topic>exemestane</topic><topic>Female</topic><topic>Greece</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Lipid Metabolism - drug effects</topic><topic>lipids</topic><topic>Lipids - blood</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Postmenopause - blood</topic><topic>Postmenopause - drug effects</topic><topic>Postmenopause - metabolism</topic><topic>tamoxifen</topic><topic>Tamoxifen - therapeutic use</topic><topic>TEAM trial</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Markopoulos, C.</creatorcontrib><creatorcontrib>Polychronis, A.</creatorcontrib><creatorcontrib>Dafni, U.</creatorcontrib><creatorcontrib>Koukouras, D.</creatorcontrib><creatorcontrib>Zobolas, V.</creatorcontrib><creatorcontrib>Tzorakoleftherakis, E.</creatorcontrib><creatorcontrib>Xepapadakis, G.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Markopoulos, C.</au><au>Polychronis, A.</au><au>Dafni, U.</au><au>Koukouras, D.</au><au>Zobolas, V.</au><au>Tzorakoleftherakis, E.</au><au>Xepapadakis, G.</au><au>Gogas, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>20</volume><issue>1</issue><spage>49</spage><epage>55</epage><pages>49-55</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: The Greek substudy of the Tamoxifen and Exemestane Adjuvant Multicenter International trial compared the effect of exemestane on the lipid profile of postmenopausal, breast cancer patients to that of tamoxifen in the adjuvant setting.
Patients and methods: Lipidemic profile changes were studied in 142 postmenopausal patients randomized to receive either adjuvant exemestane (n = 77) or tamoxifen (n = 65). Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and serum triglyceride (TRG) levels were measured at baseline and then every 3 months for the first 12 months of treatment and at 18 and 24 months.
Results: A trend for a reduction in TC was found in both treatment arms; however, TC and LDL levels were consistently and significantly decreased in tamoxifen arm only. The mean HDL level was higher for the tamoxifen arm compared with the exemestane arm across time. No significant trend was detected throughout the study period on TRG levels on either arm.
Conclusions: Unlike tamoxifen's beneficial effect on TC and LDL levels, exemestane appears to have a neutral effect on lipidemic profile of postmenopausal, breast cancer patients. These data offer additional information with regard to the safety and tolerability of exemestane treatment in the adjuvant setting.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>18678766</pmid><doi>10.1093/annonc/mdn545</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2009-01, Vol.20 (1), p.49-55 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_journals_196631980 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - blood Adenocarcinoma - drug therapy Adenocarcinoma - metabolism Adenocarcinoma - surgery Androstadienes - adverse effects Androstadienes - therapeutic use Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use aromatase inhibitors Biological and medical sciences breast cancer Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - surgery Chemotherapy, Adjuvant cholesterol Cross-Over Studies exemestane Female Greece Gynecology. Andrology. Obstetrics Humans Lipid Metabolism - drug effects lipids Lipids - blood Mammary gland diseases Medical sciences Pharmacology. Drug treatments Postmenopause - blood Postmenopause - drug effects Postmenopause - metabolism tamoxifen Tamoxifen - therapeutic use TEAM trial Tumors |
| title | Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A48%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20changes%20in%20breast%20cancer%20patients%20on%20exemestane%20treatment:%20final%20results%20of%20the%20TEAM%20Greek%20substudy&rft.jtitle=Annals%20of%20oncology&rft.au=Markopoulos,%20C.&rft.date=2009-01-01&rft.volume=20&rft.issue=1&rft.spage=49&rft.epage=55&rft.pages=49-55&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdn545&rft_dat=%3Cproquest_cross%3E1631051301%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196631980&rft_id=info:pmid/18678766&rft_oup_id=10.1093/annonc/mdn545&rft_els_id=S0923753419399612&rfr_iscdi=true |